Bouygues SA : In an accumulation phase
Entry price | Target | Stop-loss | Potential |
---|
€34.84 |
€38.8 |
€32.8 |
+11.37% |
---|
The price of Bouygues shares is range-bound. This phase will end sooner or later when volatility comes back.
Summary● The company has strong fundamentals. More than 70% of listed companies have a lower mix of growth, profitability, debt and visibility criteria.
● The company has solid fundamentals for a short-term investment strategy.
Strengths● The group usually releases upbeat results with huge surprise rates.
● The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.43 for the 2021 fiscal year.
● With a P/E ratio at 13.35 for the current year and 11.66 for next year, earnings multiples are highly attractive compared with competitors.
● This company will be of major interest to investors in search of a high dividend stock.
● The stock is in a well-established, long-term rising trend above the technical support level at 30 EUR
Weaknesses● Stock prices approach a strong long-term resistance in weekly data at EUR 35.65.
● With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
● The company does not generate enough profits, which is an alarming weak point.
The content herein constitutes a general investment recommendation, prepared in accordance with provisions aimed at preventing market abuse by Surperformance, the publisher of MarketScreener.com. More specifically, this recommendation is based on factual elements and expresses a sincere, complete, and balanced opinion. It relies on internal or external data, considered reliable as of the date of their release. Nevertheless, this information, and the resulting recommendation, may contain inaccuracies, errors, or omissions, for which Surperformance cannot be held responsible. This recommendation, which in no way constitutes investment advice, may not be suitable for all investor profiles. The reader acknowledges and accepts that any investment in a financial instrument involves risks, for which they assume full responsibility, without recourse against Surperformance. Surperformance commits to disclosing any conflict of interest that may affect the objectivity of its recommendations.